

Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/SD197360433CEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: SD197360433CEN

Abstracts

The 7 major septic shock markets are expected to exhibit a CAGR of 6.53% during 2024-2034.

The septic shock market has been comprehensively analyzed in IMARC's new report titled "Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Septic shock refers to a life-threatening condition that occurs when the body's immune response to an infection becomes overwhelming and causes widespread inflammation throughout the body. The symptoms of the ailment can develop rapidly and include fever, chills, rapid heart rate, confusion or disorientation, decreased urine output, abdominal pain, nausea, vomiting, skin rash, etc. As the condition progresses, septic shock can lead to severe hypotension, respiratory failure, acute kidney injury, and cardiac arrest. The diagnosis of the ailment is based on a combination of clinical evaluation and laboratory testing. Medical professionals will evaluate the patient's symptoms and perform a physical examination, including monitoring blood pressure, heart rate, respiratory rate, etc. Blood tests help in identifying the presence of an infection as well as markers of inflammation and organ dysfunction. Several imaging studies, such as chest X-rays or CT scans, are also used to locate the source of the infection. In some cases, medical professionals may perform various invasive procedures, including blood cultures and a lumbar puncture, to help identify the specific organism causing the infection.

The increasing cases of bacterial, fungal, viral, and parasitic infections, which lead to systemic inflammation as well as widespread organ dysfunction, are primarily driving the septic shock market. Additionally, the rising prevalence of various associated risk factors, including advancing age, weakened immune system, chronic illness, invasive

medical procedures, etc., is also bolstering the market growth. Moreover, the escalating adoption of broad-spectrum antibiotics to control the infection and prevent further damage to the body is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of vasopressors, such as norepinephrine, epinephrine, dopamine, etc., since they increase blood pressure and enhance blood flow to vital organs, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of biomarkers that can aid in the diagnosis, risk stratification, and monitoring of septic shock patients. This, in turn, is also propelling the market growth. Additionally, the inflating utilization of immunomodulation agents, including corticosteroids, intravenous immunoglobulin, granulocyte-macrophage colony-stimulating factor, etc., to modulate the immune response and restore immune homeostasis is expected to drive the septic shock market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the septic shock market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for septic shock and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the septic shock market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the septic shock market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the septic shock market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current septic shock marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the septic shock market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the septic shock market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the septic shock market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of septic shock across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of septic shock by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of septic shock by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with septic shock across the seven major markets?

What is the size of the septic shock patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of septic shock?

What will be the growth rate of patients across the seven major markets?

Septic Shock: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for septic shock drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the septic shock market?

What are the key regulatory events related to the septic shock market?

What is the structure of clinical trial landscape by status related to the septic shock market?

What is the structure of clinical trial landscape by phase related to the septic shock market?

What is the structure of clinical trial landscape by route of administration related to the septic shock market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SEPTIC SHOCK - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 SEPTIC SHOCK - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 SEPTIC SHOCK - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 SEPTIC SHOCK - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 SEPTIC SHOCK - UNMET NEEDS

10 SEPTIC SHOCK - KEY ENDPOINTS OF TREATMENT

11 SEPTIC SHOCK - MARKETED PRODUCTS

- 11.1 List of Septic Shock Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Giapreza (Angiotensin II) - La Jolla Pharmaceutical Company
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 SEPTIC SHOCK - PIPELINE DRUGS

12.1 List of Septic Shock Pipeline Drugs Across the Top 7 Markets

12.1.1 Adrecizumab - Adrenomed

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 Centhaquine - Pharmazz

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 OctaplasLG - Octapharma

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 GEM 00220 - Northern Therapeutics

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

12.1.5 Nangibotide - Inotrem

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. SEPTIC SHOCK - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SEPTIC SHOCK – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 SEPTIC SHOCK - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Septic Shock - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Septic Shock - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Septic Shock - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Septic Shock - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Septic Shock - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Septic Shock - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Septic Shock - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Septic Shock - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Septic Shock - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Septic Shock - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Septic Shock - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Septic Shock - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Septic Shock - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Septic Shock - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Septic Shock - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Septic Shock - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Septic Shock - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Septic Shock - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Septic Shock - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Septic Shock - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Septic Shock - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Septic Shock - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Septic Shock - Access and Reimbursement Overview

16 SEPTIC SHOCK - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SEPTIC SHOCK MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 SEPTIC SHOCK MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/SD197360433CEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SD197360433CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

